Date Release
December 7

Otsuka and Lundbeck Present Data at ACNP Annual Meeting on Long-Acting Injectable Aripiprazole as a Potential Maintenance Treatment for Bipolar I Disorder

December 2

Takeda and Lundbeck Take Innovative Approach To Connecting With People Living With Major Depressive Disorder (MDD)  

December 2 Citizens United for Research in Epilepsy (CURE) and Lundbeck Announce National Launch of Education Enrichment Fund
November 30 FDA Accepts For Review A Supplemental New Drug Application To Expand Labeling Of ABILIFY MAINTENA® (aripiprazole) For The Treatment Of Bipolar I Disorder
November 16 Connect 4 Mental Health™ Announces 2016 Community Innovation Award Recipients
October 7 FDA Approves Carnexiv™ (carbamazepine) injection as Intravenous Short-Term Replacement Therapy for Certain Seizure Types
September 28 Post-Hoc Analysis of Open-Label Extension Study Assesses the use of ONFI® (clobazam) CIV and the Potential for Tolerance
September 23 U.S. FDA Approves Labeling Update of Rexulti® (brexpiprazole) For Maintenance Treatment of Schizophrenia
July 7 Idalopirdine granted Fast Track Designation by U.S. Food and Drug Administration (FDA)
June 23 U.S. FDA Approves Changes to the SABRIL® (vigabatrin) REMS Program
June 1 Trintellix (vortioxetine) Now Available in U.S. Pharmacies
May 16 Takeda and Lundbeck Present Vortioxetine Data at the American Psychiatric Association (APA) 2016 Annual Meeting
May 2 Brintellix (vortioxetine) Renamed Trintellix (vortioxetine) in U.S. to Avoid Name Confusion
April 22 FDA Accepts Lundbeck Resubmission of New Drug Application for Carnexiv™ (carbamazepine)
April 20 New Initiative Sheds Light on an Often Undiagnosed Condition Associated with Parkinson’s Disease and other Nervous System Disorders
April 11 Lundbeck to Present Data on Alzheimer’s, Epilepsy and Movement Disorder Medicines at AAN
April 7 Patient Groups Rank Lundbeck US First in Corporate Reputation Among Top Pharmaceutical Companies
March 28 Takeda and Lundbeck Receive Complete Response Letter for Brintellix® (vortioxetine) sNDA
February 11 Results of New Survey Show Nearly Two Thirds of Surveyed Adults with Major Depressive Disorder (MDD) Who Report Taking Their Medication As Prescribed Still Experience Symptoms at Least Weekly
February 8

U.S. FDA Accepts for Review Otsuka and Lundbeck’s sNDA Filing for Labeling Update of REXULTI® (brexpiprazole) for Maintenance Treatment of Schizophrenia

February 3

FDA Psychopharmacologic Drug Advisory Committee Supports the Effectiveness of Brintellix® (vortioxetine) in Treating Certain Aspects of Cognitive Dysfunction in Major Depressive Disorder (MDD)

Contact Us


Ashleigh Duchene
Associate Director, Public Relations
Email: ADUC@lundbeck.com
Phone: 312-802-2906


Rachel Vann
Senior Manager, Public Relations
Email: RVAN@lundbeck.com
Phone: 224-507-8401

Follow us on Twitter!

Get our latest company news.
Click here

You have chosen to visit another Lundbeck website or a third-party website, which is provided as a service to you. Lundbeck does not control content on third-party websites and cannot make representations concerning the accuracy of information on every website you visit. Lundbeck is not responsible for the privacy policy of any third-party website. We encourage you to read the privacy policy of every website you visit. Click OK to continue or Cancel to return to Lundbeck.